SCHEMBL7302879

SCHEMBL7302879

CCC(C(=O)c1ccccc1)N1CCNCC1

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
OPRD1 P41143 9/20 0.60
SLC6A3 Q01959 4/20 0.58
SLC6A2 P23975 3/20 0.58
HSP90AA1 P07900 1/20 0.50
OPRM1 P35372 2/20 0.49
SIGMAR1 Q99720 1/20 0.49
DRD3 P35462 1/20 0.48
SLC6A4 P31645 3/20 0.48
OPRK1 P41145 1/20 0.45
USP2 O75604 1/20 0.44
ALDH1A1 P00352 1/20 0.44
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4939421 0.86 SLC6A3 (0.77) SLC6A3SLC6A2HSP90AA1SLC6A4
SCHEMBL11665417 0.84 SLC6A3 (0.75) SLC6A3SLC6A2HSP90AA1SLC6A4ALDH1A1
SCHEMBL27513426 0.83 SLC6A2 (0.50) OPRD1SLC6A3SLC6A2HSP90AA1OPRM1
SCHEMBL3401494 0.82 SLC6A2 (0.49) OPRD1SLC6A3SLC6A2HSP90AA1OPRM1
SCHEMBL501353 0.82 HSD17B10 (0.61) SLC6A3SLC6A2HSP90AA1DRD3SLC6A4
SCHEMBL4313458 0.81 HSP90AA1 (0.59) SLC6A3SLC6A2HSP90AA1DRD3SLC6A4
SCHEMBL4869220 0.80 OPRD1 (0.53) OPRD1SLC6A3SLC6A2OPRM1SIGMAR1
SCHEMBL28598873 0.79 SIGMAR1 (0.56) OPRD1SLC6A3SLC6A2OPRM1SIGMAR1
Hydrochloric Acid SCHEMBL27492948 0.78 OPRD1 (0.52) OPRD1SLC6A3SLC6A2OPRM1SIGMAR1
SCHEMBL1494478 0.77 SIGMAR1 (0.43) OPRD1SLC6A3SLC6A2OPRM1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-5238934-A None JP disclosed
EP-0538897-B1 The use of BMY 14802 in the treatment of anxiety in benzodiazepine-withdrawn patients BRISTOL MYERS SQUIBB CO (US) 1997-03-26 EP disclosed
US-5278164-A Treatment of anxiety in benzodiazepine-withdrawn patients BRISTOL-MYERS SQUIBB CO. (US) 1994-01-11 US disclosed
JP-H05238934-A ANTIDEPRESSANT BRISTOL MYERS SQUIBB CO 1993-09-17 JP disclosed
EP-0538897-A1 The use of BMY 14802 in the treatment of anxiety in benzodiazepine-withdrawn patients Bristol-Myers Squibb Company (US) 1993-04-28 EP disclosed
US-5055470-A METHOD OF TREATMENT OF ISCHEMIA IN BRAIN BRISTOL-MYERS SQUIBB CO. (US) 1991-10-08 US disclosed
US-4994460-A Treatment or prevention of disorders resulting from central nervous system anoxia BRISTOL-MYERS SQUIBB CO. (US) 1991-02-19 US disclosed
EP-0410114-A2 Use of 4-[4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl]-1-(4-fluorophenyl)-butanol in pharmaceutical compositions for the treatment of ischemia in brain Bristol-Myers Squibb Company (US) 1991-01-30 EP disclosed
EP-0400661-A1 Agents for treatment of brain ischemia Bristol-Myers Squibb Company (US) 1990-12-05 EP disclosed
US-4605655-A NEUROLEPTIC AGENTS; NO MOVEMENT DISORDER SIDE EFFECTS BRISTOL-MYERS COMPANY (US) 1986-08-12 US disclosed
US-3933824-A Piperazinobutyrophenone derivatives SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1976-01-20 US disclosed